- Home
- CLPR vs IBIO Comparison
CLPR vs IBIO Comparison
Compare CLPR & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | IBIO |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.2M | 52.8M |
| IPO Year | 2015 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CLPR | IBIO |
|---|---|---|
| Price | $3.23 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.69 |
| AVG Volume (30 Days) | 24.0K | ★ 646.8K |
| Earning Date | 11-04-2026 | 11-16-2026 |
| Dividend Yield | ★ 11.52% | N/A |
| EPS Growth | N/A | ★ 81.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | $0.91 | N/A |
| Revenue Next Year | $2.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $2.69 | $0.69 |
| 52 Week High | $3.94 | $3.82 |
Technical Indicators
Market Signals| Indicator | CLPR | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 37.87 |
| Support Level | $3.09 | $0.71 |
| Resistance Level | $3.28 | $1.52 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 33.33 | 33.63 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About IBIO iBio Inc.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.